Fundic gland polyp Medical Services in China

Fundic gland polyp (FGP) is the most common type of gastric polyp, typically arising from the fundus and body of the stomach. These are benign, non-neoplastic lesions composed of dilated, cystically enlarged fundic glands lined by parietal and chief cells—without dysplasia in the vast majority of sporadic cases. FGPs are usually discovered incidentally during upper gastrointestinal endoscopy performed for unrelated indications such as dyspepsia, reflux, or anemia. Pathogenetically, sporadic FGPs are strongly associated with long-term proton pump inhibitor (PPI) use, likely due to PPI-induced hypergastrinemia leading to fundic gland hyperplasia. In contrast, FGPs occurring in the context of familial adenomatous polyposis (FAP) are genetically driven (APC gene mutations) and carry a higher, albeit still low, risk of dysplasia—particularly when larger (>1 cm), numerous (>20), or histologically atypical. Epidemiologically, FGPs are found in approximately 0.8–2.5% of routine upper endoscopies in Western populations and up to 5–8% in patients on chronic PPI therapy; they are more prevalent in middle-aged and older adults (peak incidence 50–70 years), with a slight female predominance. Risk factors include prolonged PPI use (>1 year), age >50, female sex, and—critically—undiagnosed or untreated FAP. While most FGPs are asymptomatic and do not impair quality of life directly, their incidental discovery often triggers patient anxiety about cancer risk, unnecessary repeat endoscopies, and healthcare overutilization. Larger or multiple polyps may rarely cause nonspecific symptoms such as epigastric discomfort or occult gastrointestinal bleeding, but these are uncommon. Importantly, FGPs themselves do not cause functional gastric impairment, nor do they alter digestion or nutrient absorption. However, persistent concern about malignancy, repeated surveillance endoscopies, and potential overtreatment can negatively affect psychological well-being and daily functioning—especially among health-anxious individuals. Management focuses on accurate diagnosis (via high-definition endoscopy with targeted biopsy), risk stratification (sporadic vs. FAP-associated), and judicious surveillance rather than routine resection. Current guidelines (e.g., ACG, ESGE) recommend no removal for typical small (<1 cm), isolated, histologically confirmed sporadic FGPs, reserving endoscopic resection for lesions with suspicious features (size ≥1 cm, irregular surface, ulceration, or dysplasia on biopsy) or in confirmed FAP patients. Patient education regarding the overwhelmingly benign nature of sporadic FGPs—and the importance of evaluating for underlying FAP in young patients or those with multiple polyps—is essential to alleviate distress and optimize long-term outcomes.

Fundic gland polyps (FGPs) are the most common gastric polyps encountered in clinical practice, typically discovered incidentally during upper gastrointestinal endoscopy. They arise from hyperplasia of the fundic gland mucosa—primarily parietal and chief cells—in the gastric fundus and body. FGPs are almost always benign, with an exceedingly low malignant potential (<0.1%), particularly in sporadic cases not associated with familial adenomatous polyposis (FAP). Management is therefore largely conservative and risk-stratified, guided by polyp size, number, morphology, histopathological features, and underlying clinical context.

Conservative treatment constitutes the cornerstone of management for the vast majority of patients. Sporadic FGPs smaller than 10 mm, solitary or few in number (≤5), and without dysplasia on biopsy require no intervention beyond surveillance. Current guidelines—including those from the American College of Gastroenterology (ACG) and the European Society of Gastrointestinal Endoscopy (ESGE)—recommend baseline endoscopic evaluation with high-definition white-light endoscopy (HD-WLE) and targeted biopsies to confirm histology and exclude dysplasia or coexisting lesions. For confirmed sporadic FGPs <10 mm without dysplasia, surveillance endoscopy is generally unnecessary unless new symptoms (e.g., epigastric pain, bleeding, anemia) emerge or polyp characteristics change. In contrast, patients with FAP-associated FGPs warrant lifelong surveillance due to increased gastric cancer risk, though even in this cohort, FGPs themselves rarely progress to malignancy; rather, attention focuses on detecting concomitant gastric adenomas or early gastric cancers.

Pharmacologic therapy has no established role in inducing regression or preventing recurrence of FGPs. Proton pump inhibitors (PPIs), widely used for acid-related disorders, have been epidemiologically linked to increased FGP prevalence—likely reflecting a reactive, non-neoplastic mucosal response to chronic acid suppression. However, discontinuation of PPIs does not reliably cause polyp regression, nor is it recommended solely for FGP management. There is no evidence supporting the use of aspirin, NSAIDs, COX-2 inhibitors, or chemopreventive agents for FGPs. Therefore, medication is not indicated for treatment but may be continued or adjusted based on underlying indications (e.g., GERD, peptic ulcer disease), with shared decision-making regarding long-term PPI use.

Surgical treatment is exceptionally rare and reserved only for highly selected scenarios. Endoscopic resection—specifically cold snare polypectomy (CSP) or, less commonly, hot snare polypectomy—is the standard intervention when therapeutic removal is warranted. Indications include: (1) polyps ≥10 mm (due to slightly elevated dysplasia risk and technical challenges in accurate biopsy sampling); (2) polyps with suspicious endoscopic features (e.g., nodularity, surface erosion, irregular margins); (3) histologically confirmed low-grade dysplasia (LGD), especially if incompletely sampled or recurrent; and (4) symptomatic polyps (e.g., causing chronic occult bleeding or obstruction). Endoscopic mucosal resection (EMR) may be employed for larger or flat lesions (>15 mm), while endoscopic submucosal dissection (ESD) is rarely needed and typically reserved for lesions with unequivocal high-grade dysplasia or early invasive carcinoma—conditions that are extraordinarily uncommon in true FGPs. Surgical gastrectomy has no role in isolated FGP management and would only be considered in the context of multifocal advanced neoplasia or invasive gastric cancer, which represents a distinct pathological process.

Treatment advantages in China reflect advances in endoscopic infrastructure, expertise, and integrated care models. Major tertiary hospitals—especially those affiliated with academic medical centers in Beijing, Shanghai, Guangzhou, and Chengdu—offer state-of-the-art endoscopic platforms including magnifying endoscopy with narrow-band imaging (ME-NBI), confocal laser endomicroscopy (pCLE), and AI-assisted real-time histology prediction, enabling highly accurate optical diagnosis and reducing unnecessary biopsies. Endoscopists in China undergo rigorous standardized training through the Chinese Society of Gastrointestinal Endoscopy (CSGE), with high procedural volumes ensuring proficiency in CSP and EMR. Furthermore, China’s national endoscopic quality improvement initiatives emphasize complete resection rates, retrieval efficiency, and histopathological correlation—critical for reliable FGP characterization. Cost-effectiveness is another advantage: endoscopic resection in China is significantly more affordable than in Western countries, with minimal out-of-pocket expense for insured patients under the National Basic Medical Insurance scheme. Importantly, multidisciplinary tumor boards routinely review complex gastric polyp cases, facilitating timely referral to surgical oncology or genetics services when FAP or hereditary syndromes are suspected.

Recovery following endoscopic resection of FGPs is typically rapid and uncomplicated. Patients are advised to resume clear liquids 2–4 hours post-procedure and advance to soft, bland foods within 24 hours. A 3–5 day course of proton pump inhibitor therapy (e.g., esomeprazole 40 mg daily) is recommended to promote mucosal healing and reduce post-polypectomy bleeding risk—even in asymptomatic individuals. Heavy lifting, vigorous exercise, and NSAID use should be avoided for 7 days. Most patients return to normal activities within 48–72 hours. Follow-up endoscopy is individualized: for completely resected, non-dysplastic FGPs ≥10 mm, repeat examination in 12 months is reasonable to assess for recurrence or metachronous lesions; however, recurrence rates are low (<5% at 3 years), and long-term surveillance intervals can be extended in stable patients. Lifestyle counseling emphasizes balanced nutrition, smoking cessation, and moderation of alcohol intake—not because these directly affect FGPs, but as part of holistic gastric health maintenance. Patients with newly diagnosed FAP require coordinated genetic counseling, annual upper endoscopy starting at age 20–25, and consideration of prophylactic colectomy per international guidelines. Finally, all patients should be educated that FGPs are overwhelmingly benign and that anxiety about malignancy is rarely warranted—emphasizing evidence-based reassurance over routine intervention.